Shares of IOL Chemicals & Pharmaceuticals were trading 4.75% lower at ₹353.90 on Monday morning following the announcement of weak Q2 FY25 results. The company reported a 49.43% decline in net profit and a 3.59% drop in sales, signaling ongoing challenges in profitability and operational efficiency.
Key Financial Highlights (Q2 FY25):
- Revenue: ₹525.75 crore, down 3.59% YoY from ₹545.30 crore in Q2 FY24.
- Net Profit: ₹19.15 crore, a significant decline of 49.43% YoY from ₹37.87 crore.
- EBITDA: Down 35% YoY, with margins shrinking to 8% from 12% in Q2 FY24.
The decline in both revenue and profitability reflects the impact of reduced demand and higher operational costs. The sharp contraction in EBITDA margin highlights increased pressure on earnings, which may be attributed to rising input costs and a challenging market environment.
The disappointing results led to a selloff in IOL Chemicals & Pharmaceuticals’ stock, with investors reacting negatively to the declining profitability metrics. The company’s struggle to maintain sales growth amid margin pressures adds to concerns about its near-term performance.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Always consult a financial advisor before making investment decisions.